Moleculin Biotech, Inc. (MBRX)
MBRX moved a median of -0.30% 30 minutes after news, and -0.98% by the close. How MBRX actually reacts to news — the realized, point-in-time move the market made, measured across 429 labeled events over the last three years with zero look-ahead.
MBRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 34% | 412 |
| 30-min | -0.30% | 42% | 421 |
| 60-min | -0.58% | 39% | 425 |
| to close | -0.98% | 39% | 425 |
| Middle 50% of MBRX reactions | -3.56% to +1.56% |
|---|---|
| Median reaction (30-min) | -0.30% |
| Measured reactions | 429 |
Half of all Moleculin Biotech, Inc. news events land between -3.56% and +1.56% at 30 minutes.
Reaction stats as of 2026-08-31. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How MBRX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 73 | 0.00% | 49% | -1.27% |
| Rating reiterations | 23 | -0.59% | 35% | -2.38% |
Last 3 years, pulled 2026-08-31. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how MBRX ranks against every other measured name →
That’s how MBRX usually reacts — get an email when it moves on news →Email me when MBRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MBRX's baseline. Nothing else.
Recent MBRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Moleculin Biotech, Inc. For: Aug 31 | SEC filing · Form 8-K | SEC EDGAR | +0.72% | +1.56% | |
| Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference | Press release | GlobeNewswire | -1.61% | +11.08% | |
| Form DEF 14A Moleculin Biotech, Inc. For: Oct 09 | SEC filing · Form DEF | SEC EDGAR | +0.42% | +1.83% | |
| Form DEFA14A Moleculin Biotech, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.42% | +1.83% | |
| Form 8-K Moleculin Biotech, Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -1.67% | +2.03% | |
| Form PRE 14A Moleculin Biotech, Inc. For: Oct 09 | SEC filing · Form PRE | SEC EDGAR | -3.63% | -4.89% | |
| Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial | Press release | GlobeNewswire | -1.67% | +2.03% | |
| Form 10-Q Moleculin Biotech, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.67% | +2.03% | |
| Form 8-K Moleculin Biotech, Inc. For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | -8.88% | -6.74% | |
| Form EFFECT Moleculin Biotech, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -38.87% | +14.87% | |
| Form 8-K Moleculin Biotech, Inc. For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | +5.66% | -54.55% | |
| Form S-1/A Moleculin Biotech, Inc. | SEC filing · Form S-1 | SEC EDGAR | +5.66% | -54.55% | |
| Moleculin Announces Pricing of $9.3 Million Public Offering | Press release | GlobeNewswire | — | +6.67% | |
| Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients | Press release | GlobeNewswire | +5.66% | -54.55% | |
| Form S-1/A Moleculin Biotech, Inc. | SEC filing · Form S-1 | SEC EDGAR | +5.66% | -54.55% | |
| Form S-1 Moleculin Biotech, Inc. | SEC filing · Form S-1 | SEC EDGAR | -23.24% | -36.60% | |
| Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment | Press release | GlobeNewswire | +0.00% | -7.34% | |
| Form 8-K Moleculin Biotech, Inc. For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | -2.33% | -7.31% | |
| Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control | Press release | GlobeNewswire | -2.33% | -7.31% | |
| Form 8-K Moleculin Biotech, Inc. For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | -0.39% | -6.62% | |
| Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML | Press release | GlobeNewswire | -0.39% | -6.62% | |
| Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment | Press release | GlobeNewswire | +0.67% | +2.03% | |
| Form 8-K Moleculin Biotech, Inc. For: May 29 | SEC filing · Form 8-K | SEC EDGAR | -2.20% | +2.20% | |
| Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits | Press release | GlobeNewswire | -2.20% | +2.20% | |
| Form 8-K Moleculin Biotech, Inc. For: May 26 | SEC filing · Form 8-K | SEC EDGAR | -1.24% | +1.24% | |
| Form 8-K Moleculin Biotech, Inc. For: May 22 | SEC filing · Form 8-K | SEC EDGAR | -1.24% | +1.24% | |
| Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin | Press release | GlobeNewswire | +1.65% | -1.24% | |
| Form 8-K Moleculin Biotech, Inc. For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -5.09% | -2.31% | |
| Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial | Press release | GlobeNewswire | -5.09% | -2.31% | |
| Form 10-Q Moleculin Biotech, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -5.09% | -2.31% | |
| Form 8-K Moleculin Biotech, Inc. For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -0.04% | -12.65% | |
| Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks | Press release | GlobeNewswire | -0.04% | -12.65% | |
| Form 8-K Moleculin Biotech, Inc. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +0.82% | -4.10% | |
| Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits | Press release | GlobeNewswire | +0.82% | -4.10% | |
| Form 8-K Moleculin Biotech, Inc. For: May 08 | SEC filing · Form 8-K | SEC EDGAR | -1.99% | -1.59% | |
| Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin | Press release | GlobeNewswire | -1.99% | -1.59% | |
| Form 8-K Moleculin Biotech, Inc. For: Apr 23 | SEC filing · Form 8-K | SEC EDGAR | -0.47% | +2.83% | |
| Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026 | Press release | GlobeNewswire | -0.47% | +2.83% | |
| Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting | Press release | GlobeNewswire | +0.00% | -1.56% | |
| Form 8-K Moleculin Biotech, Inc. For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | +0.83% | +1.25% | |
| Form EFFECT Moleculin Biotech, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -1.67% | +0.00% | |
| Form 10-K/A Moleculin Biotech, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.67% | +0.00% | |
| Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile | Press release | GlobeNewswire | -1.04% | +0.21% | |
| Form S-3 Moleculin Biotech, Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.72% | -5.88% | |
| Form 8-K Moleculin Biotech, Inc. For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | +1.42% | -0.94% | |
| Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout | Press release | GlobeNewswire | +1.42% | -0.94% | |
| Form 8-K Moleculin Biotech, Inc. For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | -0.84% | -0.96% | |
| Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026 | Press release | GlobeNewswire | -0.84% | -0.96% | |
| Form 10-K Moleculin Biotech, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.84% | -0.96% | |
| Moleculin to Present at 38th Annual ROTH Conference | Press release | GlobeNewswire | +0.00% | +3.85% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MBRX section they belong to.
Where else MBRX is measured.
MBRX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CRH MEDICAL CORP (CRHM) | 431 | 0.00% | 39% |
| LeMaitre Vascular, Inc. (LMAT) | 430 | +0.06% | 53% |
| Emergent BioSolutions Inc. (EBS) | 427 | -0.22% | 46% |
| Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (KNSA) | 426 | -0.21% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Moleculin Biotech, Inc.'s median reaction calculated?
Every labeled MBRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 429 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of MBRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-31.
Does MBRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.